Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News: Buyer Group International, Inc. is Pleased to Announce That Dr. Michael Curran, an Expert in His Field with a PhD in Ecology, Has Been Appointed as the New Head of Environmental Sustainability
https://finance.yahoo.com/news/buyer-group-international-inc-pleased-120000638.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
NEWS: Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
https://ceo.ca/@GlobeNewswire/revive-therapeutics-provides-update-on-psilocybin-clinical-b2e9a
News: Buyer Group International, Inc. Releases the Shambhala 2024 Underground Exploration Plan & Maiden Drilling Proposal
19 Mar 2024, 05:03
https://www.accesswire.com/844291/buyer-group-international-inc-releases-the-shambhala-2024-underground-exploration-plan-maiden-drilling-proposal
News: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
March 19, 2024
https://www.globenewswire.com/en/news-release/2024/03/19/2848420/0/en/Revive-Therapeutics-To-Submit-Type-C-Meeting-Request-with-FDA-for-Bucillamine-to-Treat-Long-COVID.html
Preparing to drill this season!
Drilling right into the mineralization at the end of the tunnel on claim 71 could result in some powerful core data like the major sulfides of the New Rambler deposit.
Should see airborne survey data soon too
$BYRG preparing to drill this season!
— Stone (@Stonemonsta2) March 15, 2024
Drilling right into the mineralization at the end of the tunnel on claim 71 could result in some powerful core data like the major sulfides of the New Rambler deposit.
Should see airborne survey data soon too#copper #platinum #palladium https://t.co/JpkLlgYfBy pic.twitter.com/OUQ4OqQdyP
NEWS: Buyer Group International, Inc. Releases Shambhala 2024 Surface Exploration Plan
https://www.accesswire.com/841437/buyer-group-international-inc-releases-shambhala-2024-surface-exploration-plan
NEWS: Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
https://ceo.ca/@GlobeNewswire/revive-therapeutics-ltd-announces-closing-of-the-second
News: Buyer Group International, Inc. Appoints Three New Members to its Board of Directors in Anticipation of a Significant Year of Growth at Project Shambhala
Wednesday, 07 February 2024 09:00
https://www.accesswire.com/831724/buyer-group-international-inc-appoints-three-new-members-to-its-board-of-directors-in-anticipation-of-a-significant-year-of-growth-at-project-shambhala
IINX to Acquire Dalian Huagang in Strategic Logistics Move
DALIAN, China, Jan. 18, 2024
https://www.otcmarkets.com/stock/IINX/news/story?e&id=2742933
$BYRG Just got our 4th share cancellation here on this corporate cleanup. Watch for the company to start building out the team next
? 117M shares cancelled 1/26/2024
? 250M shares cancelled 1/19/2024
? 1.0B shares cancelled 12/22/2023
? 1.4B shares cancelled 4/21/2023
$BYRG Just got our 4th share cancellation here on this corporate cleanup. Watch for the company to start building out the team next 👀
— slfairless (@slfairless) January 28, 2024
117M shares cancelled 1/26/2024 ✔️
250M shares cancelled 1/19/2024 ✔️
1.0B shares cancelled 12/22/2023 ✔️
1.4B shares cancelled 4/21/2023 ✔️ pic.twitter.com/ZItWJhzIYG
News: Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
https://ir.skyebioscience.com/news-events/press-releases/detail/183/skye-bioscience-and-tautomer-bioscience-enter-exclusive
Hmmm, it looks Verified to me!!!
https://www.otcmarkets.com/stock/ICOA/overview
This is what it reads if unable to open link...
INVESTORS UPDATE November 8, 2023
As many of you are aware, MJWL underwent a merger in 2021. To demonstrate the long-term commitment to the business and minority shareholders, the shareholdings of the incoming promoters and advisors were locked in for 24 months from the merging date.
The Board of Directors and the executive team worked tirelessly to expand by bringing in new businesses under the fold of MJWL. In order to meet the funding requirements for the investments, MJWL signed a merger deal with OTEC in 2022. However the merger felt apart halfway through the process because of the ongoing issue of “Caveat Emptor” status accorded by the OTC Markets on MJWL.
Regrettably, this was due to the allegations against intermediary/brokers involved in the transactions, accusing them of stock manipulation, commonly known as pump and dump schemes. The ongoing legal proceedings and details of the case can be accessed Through this link: [Click Here to Read more] The first tribunal judgement, available from page 30 onwards via the same link, sheds light on the matter.
Based on the information available online, it appears that these alleged bad actors orchestrated a conspiracy pian as part of their “get-rich quick scheme.” In response to the situation, the management of MJWL took swift action. They appointed a seasoned public company veteran as the chairman of the company to spearhead restructuring efforts and elevate the companies to new heights. Additionally, leading law firms were engaged to collaborate with OTC markets to address the issues and lift the CE (Caveat Emptor) status on the stocks.
We would like to categoricatly state that the current management, stakeholders, nor anyone associated with the company has been implicated in the investigation.
The management and stakeholders have tirelessly collaborated with legal experts to provide all necessary information to OTC markets, aiming to fulfill the requirements and facilitate the removal of the CE status. OTC markets has been cooperative, working closely with the management to navigate through the challenges. Despite the management's full compliance and ongoing efforts, it appears that the lifting of the CE status by OTC Markets remains contingent upon the conclusion of the legal proceedings.
MJWL remains dedicated to transparency and integrity in business and the Company would like to express its thanks to all its stakeholders for the understanding and continued support.
MAJIC WHEELS CORPORATION, a Delaware Corporation (File Number 4317767) of 2401 Fountain View Drive, Suite 312, Houston, TX 77057, USA
Interesting & positive news today about MJWL...
https://twitter.com/scani_tu/status/1722263054724026817/photo/1
Interesting & positive news today about MJWL...
https://twitter.com/scani_tu/status/1722263054724026817/photo/1
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
November 06, 2023
https://www.globenewswire.com/news-release/2023/11/06/2774002/0/en/Revive-Therapeutics-Enters-into-Worldwide-Exclusive-Agreement-with-Lawson-Health-Research-Institute-to-Develop-and-Commercialize-a-Novel-Long-COVID-Rapid-Test.html
I'm starting to have similar thoughts too now..
I came across this link a few weeks ago while reading some random news that drew me down the rabbit hole of curiosity to know more...
https://twitter.com/TruthFansMatter/status/1663191437083648001?s=20
It doesn't appear to be fake news but, feel free to let me know if I'm misguided, as the 2nd clip (21mins long) was situated in a Brussels conference while the 3rd clip (19mins long) in a round about way support it. Together, it's mind blowing on how it touches on the orignal history of Covid and the Vaccine disinformation campaign.
Not trying to be a conspiracy person as my Family and I took the Covid shot like a good citizen during the pandemic. It was interesting listening for the sake of knowing more about something without being naive on the topic.
In all, as an investore trying to recoup from this, it made me wonder if RVVTF's potential success that many raved about was also misguided into this BP rabbit hole.
Shared from CEO APP: Interesting Article about $RVV $RVVTF posted by Equity Guru on Oct. 27, 2023
https://equity.guru/2023/10/27/revive-therapeutics-rvv-c-get-in-losers-were-fighting-chemical-warfare/
NEWS: Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
https://ceo.ca/@GlobeNewswire/revive-therapeutics-announces-initiation-of-novel-bucillamine
News: Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion
https://www.newsfilecorp.com/release/169568
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
https://www.stocktitan.net/news/RVVTF/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-cftqzipsz44v.html
Skye Bioscience Begins Dosing Fifth of Six Cohorts in Phase 1 Clinical Trial of Novel CB1R Agonist
https://www.newsfilecorp.com/release/166391
Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion
https://www.newsfilecorp.com/release/166109
NEWS: Skye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R Agonist
https://www.newsfilecorp.com/release/163940
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
April 18, 2023 18:44 ET
https://www.globenewswire.com/news-release/2023/04/18/2649628/0/en/Revive-Therapeutics-Provides-Update-of-Phase-3-Clinical-Study-for-Bucillamine-in-the-Treatment-of-COVID-19.html
News: Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion
Enrollment started for multiple ascending dose arm of Phase 1 study
https://www.newsfilecorp.com/release/161189
News: Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
https://www.stocktitan.net/news/RVVTF/revive-therapeutics-advances-mdma-transdermal-patch-development-with-ohg1cm9pkwbb.html
News: Skye Bioscience's Novel Cannabinoid Derivative Reduces Pain in Animal Model; Results Published in Scientific Journal
https://www.newsfilecorp.com/release/160992
NEWS:
Skye Bioscience Receives Human Research Ethics Committee Approval to Start Multiple Ascending Dose Arm of Phase 1 Study of SBI-100 Ophthalmic Emulsion
https://www.newsfilecorp.com/release/158513
NEWS: Skye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
https://www.newsfilecorp.com/release/157499
San Diego, California--(Newsfile Corp. - March 7, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, has completed dosing of the third cohort of eight healthy participants in its Phase 1 clinical trial of its lead product candidate, SBI-100 Ophthalmic Emulsion ("OE"), a cannabinoid receptor type 1 ("CB1R") agonist administered topically onto the eye. The study's safety review committee ("SRC") provided a positive recommendation following a pre-specified review of the data from the second cohort of participants. The SRC also recommended the trial advance into the multiple ascending dose ("MAD") arm of the study. Skye has submitted to the human ethics review committee ("HREC") for approval to initiate the MAD arm.
The objective of this Phase 1, randomized, double-masked, placebo-controlled study is to evaluate the safety, tolerability and pharmacokinetics of SBI-100 OE. Changes in intraocular pressure will also be evaluated. Approximately 48 subjects are divided into three single ascending dose ("SAD") and then three subsequent MAD cohorts, with six participants receiving drug and two participants receiving placebo in each cohort. In the third and final SAD cohort, participants administered drug received a single topical dose of SBI-100 OE at a concentration of 2.0%, compared to concentrations of 0.5% and 1.0% in the first and second SAD cohorts.
Skye's SBI-100 OE possesses a novel molecular structure and nanoemulsion formulation that were designed to enable effective topical delivery and better penetration of a CB1R agonist into ocular tissue. In preclinical studies involving three different species, the drug resulted in enhanced therapeutic efficacy and duration of response in lowering IOP, comparing favorably to the standard of care for treating glaucoma.
NEWS: Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Study
https://www.newsfilecorp.com/release/155905
News: Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors
https://www.newsfilecorp.com/release/155012
News: Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment
https://www.newsfilecorp.com/release/154878
News: Skye Bioscience Doses Second Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
https://www.newsfilecorp.com/release/154551
News: Skye Bioscience Achieves Positive Safety Review of SBI-100 Ophthalmic Emulsion After Phase 1 First Cohort
https://www.newsfilecorp.com/release/153016
News: Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma.
https://finance.yahoo.com/news/pii-congratulates-skye-bioscience-first-130000450.html
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
https://ceo.ca/@GlobeNewswire/revive-therapeutics-to-submit-updated-briefing-package
FDA vaccine advisers 'disappointed' and 'angry' that early data about new Covid-19 booster shot wasn't presented for review last year
By Elizabeth Cohen and Naomi Thomas, CNN
Updated 9:24 AM EST, Wed January 11, 2023
https://amp.cnn.com/cnn/2023/01/11/health/moderna-bivalent-transparency/index.html